Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
There is still time to register for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
Earlier this year Dr. Yee Ung stepped down from his position as the co-chair of the CCTG Lung Disease Site committee. The group convened a selection committee to choose a radiation oncologist as the new co-chair, over several months the committee solicited applications and interviewed several candidates. The members of the selection committee were: Drs. Penny Bradbury, Matthew Parliament, Andrea Bezjak, Yee Ung, and Joe Pater.
A secondary methodological analysis.
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
The Office of Compliance and Oversight released an updated Good Clinical Practice training course, that includes Revision 2. The revised GCP training course is available for new members who have not yet trained in GCP. A GCP refresher module, including the Revision 2 updates, was created for members who have previously completed a GCP training course. GCP training will be valid for three years from the date of completion. This training is mandatory for all members conducting clinical trials per CCTG SOPs and in compliance with NIH policy.
Clinical Research Associate (CRA) Volunteer Needed for the Breast, Gastrointestinal and Gynecologic Disease Site Executive!
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Breast, Gastrointestinal and Gynecologic Disease Site Committee Executives.
At ASCO 2019 the landmark ENZAMET | CCTG PR17 (NCT02446405) clinical trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer. Findings, show that men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in survival compared to men receiving standard treatment alone.
IND238 (NCT03847649), A Phase II Study of Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity, has been centrally activated.